Please select the option that best describes you:
Topics:
Rheumatology • Systemic lupus erythematosus
What are your thoughts on telitacicept use in SLE, and why has it not garnered more attention in US news cycle in rheumatology?
Answer from: at Community Practice
Telitacicept (a fully human TACI-Fc fusion protein that targets B lymphocyte stimulator (BLyS) and a proliferating-inducing ligand (APRIL) blocks the interaction of BLyS and APRIL, resulting in reduced B-cell proliferation and maturation. Theoretically, it makes sense that it should work in B-cell-d...
Sign In or Register to read more
Answer from: at Academic Institution
Timely question, as we just reviewed this paper in our journal club. I agree with @Donald E. Thomas that these are impressive results and certainly not what we typically observe in lupus trials. The placebo response is consistent with prior SLE studies, but the intervention arm response of 67% ...